Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Vaccines

Free Subscription Articles published in J Virol Retrieve available abstracts of 84 articles: HTML format

Single Articles

May 2025
1. KARTHIGEYAN KP, Connors M, Binuya CR, Gross M, et al
   A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice.
   J Virol. 2025 May 8:e0217824. doi: 10.1128/jvi.02178.
   PubMed     Abstract available
   
   
   
2. LUGANO D, Mwangi K, Mware B, Kibet G, et al
   Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
   J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
   PubMed     Abstract available
   
   
   April 2025
3. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
   Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
   J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
   PubMed     Abstract available
   
   
   
4. LI Y, Yang S, Qian J, Liu S, et al
   Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
   J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
   PubMed     Abstract available
   
   
   
5. THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al
   Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.
   J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229.
   PubMed     Abstract available
   
   
   
6. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
   ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
   J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
   PubMed     Abstract available
   
   
   
7. LOU Y-N, Sun M-X, Li K, Xiong X-C, et al
   A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.
   J Virol. 2025;99:e0177024.
   PubMed     Abstract available
   
   
   
8. CHENTOUFI AA, Prakash S, Vahed H, Karan S, et al
   A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.
   J Virol. 2025 Apr 10:e0013525. doi: 10.1128/jvi.00135.
   PubMed     Abstract available
   
   
   March 2025
9. BLASS E, Colarusso A, Aid M, Larocca RA, et al
   Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.
   J Virol. 2025 Mar 31:e0024725. doi: 10.1128/jvi.00247.
   PubMed     Abstract available
   
   
   
10. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
    J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253.
    PubMed     Abstract available
    
    
    
11. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed     Abstract available
    
    
    
12. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed     Abstract available
    
    
    
13. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed     Abstract available
    
    
    
14. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed     Abstract available
    
    
    
15. MLINGO TAM, Theron J, Mokoena NB
    Plasmid DNA-based reverse genetics as a platform for manufacturing of bluetongue vaccine.
    J Virol. 2025 Mar 6:e0013925. doi: 10.1128/jvi.00139.
    PubMed     Abstract available
    
    
    
16. HU H, Zhang Y, Zheng H, Zhao X, et al
    Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
    J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
    PubMed     Abstract available
    
    
    
17. KARL V, Hofmann M, Thimme R
    Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
    J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
    PubMed     Abstract available
    
    
    February 2025
18. ABBO SR, Yan K, Geertsema C, Hick TAH, et al
    Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.
    J Virol. 2025 Feb 27:e0232224. doi: 10.1128/jvi.02322.
    PubMed     Abstract available
    
    
    
19. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
    Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
    J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
    PubMed     Abstract available
    
    
    
20. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
    Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
    J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
    PubMed     Abstract available
    
    
    
21. CHEN C-X, Wang X, Su W, Tian Y, et al
    Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.
    J Virol. 2025 Feb 21:e0195424. doi: 10.1128/jvi.01954.
    PubMed     Abstract available
    
    
    
22. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed     Abstract available
    
    
    January 2025
23. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed     Abstract available
    
    
    
24. ZHAO B, Sun Z, Wang S, Shi Z, et al
    Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus.
    J Virol. 2025;99:e0140024.
    PubMed     Abstract available
    
    
    
25. SADLER HL, Rijal P, Tan TK, Townsend ARM, et al
    A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
    J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331.
    PubMed     Abstract available
    
    
    
26. KENNEDY PGE, Grose C
    Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.
    J Virol. 2025 Jan 17:e0181624. doi: 10.1128/jvi.01816.
    PubMed     Abstract available
    
    
    
27. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    PubMed     Abstract available
    
    
    
28. DSOUZA L, Pant A, Pope B, Yang Z, et al
    Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.
    J Virol. 2025 Jan 16:e0211024. doi: 10.1128/jvi.02110.
    PubMed     Abstract available
    
    
    December 2024
29. LV H, Teo QW, Lee C-CD, Liang W, et al
    Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
    J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
    PubMed     Abstract available
    
    
    November 2024
30. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
    Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
    J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
    PubMed     Abstract available
    
    
    
31. JIMENEZ-CABELLO L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, et al
    Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
    J Virol. 2024 Nov 7:e0168724. doi: 10.1128/jvi.01687.
    PubMed     Abstract available
    
    
    
32. CHEN D, Zhang W, Xiao B, Xu B, et al
    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
    J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
    PubMed     Abstract available
    
    
    
33. DAI W, Xing M, Sun L, Lv L, et al
    Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway.
    J Virol. 2024 Nov 4:e0169924. doi: 10.1128/jvi.01699.
    PubMed     Abstract available
    
    
    October 2024
34. PANT A, Brahim Belhaouari D, Dsouza L, Yang Z, et al
    Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP citrate lyase during vaccinia virus infection.
    J Virol. 2024 Oct 30:e0110324. doi: 10.1128/jvi.01103.
    PubMed     Abstract available
    
    
    
35. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    PubMed     Abstract available
    
    
    
36. ZHANG D, Xie Y, Liao Q, Jiao Z, et al
    Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2 subunit replacement.
    J Virol. 2024 Oct 15:e0042924. doi: 10.1128/jvi.00429.
    PubMed     Abstract available
    
    
    
37. WANG W, Bhushan G, Paz S, Stauft CB, et al
    Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
    PubMed     Abstract available
    
    
    
38. DO THT, Wille M, Wheatley AK, Koutsakos M, et al
    Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
    J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186.
    PubMed     Abstract available
    
    
    September 2024
39. HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al
    Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes.
    J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166.
    PubMed     Abstract available
    
    
    
40. LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al
    High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains.
    J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689.
    PubMed     Abstract available
    
    
    
41. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    PubMed     Abstract available
    
    
    
42. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    PubMed     Abstract available
    
    
    
43. SOUDANI N, Bricker TL, Darling T, Seehra K, et al
    Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528.
    PubMed     Abstract available
    
    
    August 2024
44. YING B, Liang C-Y, Desai P, Scheaffer SM, et al
    Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574.
    PubMed     Abstract available
    
    
    
45. GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al
    Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice.
    J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766.
    PubMed     Abstract available
    
    
    
46. WANG G, Verma AK, Guan X, Bu F, et al
    Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376.
    PubMed     Abstract available
    
    
    
47. UNO N, Ebensen T, Guzman CA, Ross TM, et al
    Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.
    J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354.
    PubMed     Abstract available
    
    
    
48. MOSS WJ, Griffin DE
    What's going on with measles?
    J Virol. 2024;98:e0075824.
    PubMed     Abstract available
    
    
    
49. LI J, Xiao L, Chen Z, Fan L, et al
    A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets.
    J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535.
    PubMed     Abstract available
    
    
    
50. MU Z, Whitley J, Martik D, Sutherland L, et al
    Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
    PubMed     Abstract available
    
    
    July 2024
51. WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al
    rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.
    J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781.
    PubMed     Abstract available
    
    
    
52. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
    Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
    J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
    PubMed     Abstract available
    
    
    
53. LINGEMANN M, Amaro-Carambot E, Lamirande EW, Pierson TC, et al
    Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
    J Virol. 2024;98:e0068124.
    PubMed     Abstract available
    
    
    
54. PORTUGAL R, Goldswain H, Moore R, Tully M, et al
    Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.
    J Virol. 2024;98:e0062224.
    PubMed     Abstract available
    
    
    
55. KOTAKI T, Kanai Y, Onishi M, Minami S, et al
    Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6.
    J Virol. 2024;98:e0076224.
    PubMed     Abstract available
    
    
    
56. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
    Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
    PubMed     Abstract available
    
    
    
57. ZHANG L, Yu R, Wang L, Zhang Z, et al
    Serial cell culture passaging in vitro led to complete attenuation and changes in the characteristic features of a virulent porcine deltacoronavirus strain.
    J Virol. 2024 Jul 16:e0064524. doi: 10.1128/jvi.00645.
    PubMed     Abstract available
    
    
    
58. RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al
    SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678.
    PubMed     Abstract available
    
    
    June 2024
59. ZHU J, Wang Z, Li Y, Zhang Z, et al
    Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
    PubMed     Abstract available
    
    
    
60. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
    Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
    J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
    PubMed     Abstract available
    
    
    
61. LU J, Liu J, Wu Y, He X, et al
    A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.
    J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769.
    PubMed     Abstract available
    
    
    May 2024
62. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
    Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
    J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
    PubMed    
    
    
    
63. DOETS K, Pijlman GP
    Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
    J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100.
    PubMed     Abstract available
    
    
    
64. HASHIZUME M, Takashima A, Iwasaki M
    An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
    J Virol. 2024 May 20:e0057824. doi: 10.1128/jvi.00578.
    PubMed     Abstract available
    
    
    April 2024
65. THORESEN D, Matsuda K, Urakami A, Ngwe Tun MM, et al
    A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
    J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239.
    PubMed     Abstract available
    
    
    
66. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
    Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
    J Virol. 2024;98:e0177323.
    PubMed     Abstract available
    
    
    
67. PEREZ DR
    A devastating blow: personal reflections on Argentina's scientific decline.
    J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
    PubMed     Abstract available
    
    
    
68. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
    Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
    PubMed     Abstract available
    
    
    
69. TANG X, Li S, Zhou J, Bian X, et al
    Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
    J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212.
    PubMed     Abstract available
    
    
    
70. QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al
    Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects against recurrent
    J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596.
    PubMed     Abstract available
    
    
    
71. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
    Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
    PubMed     Abstract available
    
    
    
72. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
    PubMed     Abstract available
    
    
    
73. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
    PubMed     Abstract available
    
    
    
74. ZHU Z, Han Y, Gong M, Sun B, et al
    Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957.
    PubMed     Abstract available
    
    
    March 2024
75. WU K, Hou YJ, Makrinos D, Liu R, et al
    Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
    J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
    PubMed     Abstract available
    
    
    
76. NUNBERG JH, Westover JB, York J, Jung KH, et al
    Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
    J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
    PubMed     Abstract available
    
    
    
77. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
    The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
    J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
    PubMed     Abstract available
    
    
    February 2024
78. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
    Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
    J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
    PubMed     Abstract available
    
    
    
79. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
    A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
    J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
    PubMed     Abstract available
    
    
    
80. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    PubMed     Abstract available
    
    
    
81. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
    Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
    J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
    PubMed     Abstract available
    
    
    
82. LI H, Sun H, Tao M, Han Q, et al
    Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
    J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
    PubMed     Abstract available
    
    
    
83. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
    SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
    PubMed     Abstract available
    
    
    January 2024
84. ROWE T, Davis W, Wentworth DE, Ross T, et al
    Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
    J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.